Objectives: In this longitudinal study, we assessed the role of musculoskeletal ultrasound (US) in predicting the efficacy of JAK inhibitors (JAKi) in rheumatoid arthritis (RA) patients. Methods: We enrolled RA patients starting baricitinib or tofacitinib. All patients were evaluated at baseline and after 4, 12, 24, 48 weeks. Disease activity was calculated by Disease Activity Score 28 (DAS28CRP); US examination in 22 joints (I-V MCPs and PIPs, wrists) aimed at evaluating inflammatory features (synovial effusion and hypertrophy, power Doppler-PD), scored through a semi-quantitative scale (0-3). The total US (0-198) and PD (0-66) scores were calculated. We scanned bilateral flexor (I-V fingers of hands) and extensor compartments (1-6) tendons: tenosynovitis was scored as absent/present (0/1), resulting in a total score ranging from 0 to 22. Results: We studied 102 patients (M/F 15/87; median age 59.2 years, IQR 17.75; median disease duration 144 months, IQR 126), 61 treated with baricitinib and 41 with tofacitinib. At baseline, the median total US score was 18 (IQR 19) and the median PD score 2 (4). We observed a significant reduction in both total and PD US scores at all time-points (p<0.0001). At baseline, 75.4% of patients showed tenosynovitis involving at least one tendon, with a median score of 2 (IQR 3.5) significantly decreasing after 24 weeks (p=0.02). At multivariate analysis, PD and tenosynovitis score significantly correlated with changes in DAS28CRP. Conclusions: The present study confirmed the early efficacy of JAKi in RA patients by using US evaluation. Furthermore, we found that power Doppler and tenosynovitis scores could play a predictive role in response to treatment.

The role of musculoskeletal ultrasound in predicting the response to JAK inhibitors. results from a monocentric cohort / Ceccarelli, Fulvia; Spinelli, Francesca Romana; Garufi, Cristina; Mancuso, Silvia; Alessandri, Cristiano; Di Franco, Manuela; Orefice, Valeria; Pacucci, Viviana Antonella; Pirone, Carmelo; Priori, Roberta; Riccieri, Valeria; Sili Scavalli, Antonio; Scrivo, Rossana; Truglia, Simona; Conti, Fabrizio. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 1593-098X. - 40:5(2022), pp. 921-927. [10.55563/clinexprheumatol/totvyv]

The role of musculoskeletal ultrasound in predicting the response to JAK inhibitors. results from a monocentric cohort

Ceccarelli, Fulvia
;
Spinelli, Francesca Romana;Garufi, Cristina;Mancuso, Silvia;Alessandri, Cristiano;Di Franco, Manuela;Orefice, Valeria;Pacucci, Viviana Antonella;Pirone, Carmelo;Priori, Roberta;Riccieri, Valeria;Sili Scavalli, Antonio;Scrivo, Rossana;Truglia, Simona;Conti, Fabrizio
2022

Abstract

Objectives: In this longitudinal study, we assessed the role of musculoskeletal ultrasound (US) in predicting the efficacy of JAK inhibitors (JAKi) in rheumatoid arthritis (RA) patients. Methods: We enrolled RA patients starting baricitinib or tofacitinib. All patients were evaluated at baseline and after 4, 12, 24, 48 weeks. Disease activity was calculated by Disease Activity Score 28 (DAS28CRP); US examination in 22 joints (I-V MCPs and PIPs, wrists) aimed at evaluating inflammatory features (synovial effusion and hypertrophy, power Doppler-PD), scored through a semi-quantitative scale (0-3). The total US (0-198) and PD (0-66) scores were calculated. We scanned bilateral flexor (I-V fingers of hands) and extensor compartments (1-6) tendons: tenosynovitis was scored as absent/present (0/1), resulting in a total score ranging from 0 to 22. Results: We studied 102 patients (M/F 15/87; median age 59.2 years, IQR 17.75; median disease duration 144 months, IQR 126), 61 treated with baricitinib and 41 with tofacitinib. At baseline, the median total US score was 18 (IQR 19) and the median PD score 2 (4). We observed a significant reduction in both total and PD US scores at all time-points (p<0.0001). At baseline, 75.4% of patients showed tenosynovitis involving at least one tendon, with a median score of 2 (IQR 3.5) significantly decreasing after 24 weeks (p=0.02). At multivariate analysis, PD and tenosynovitis score significantly correlated with changes in DAS28CRP. Conclusions: The present study confirmed the early efficacy of JAKi in RA patients by using US evaluation. Furthermore, we found that power Doppler and tenosynovitis scores could play a predictive role in response to treatment.
2022
JAK inhibitors; rheumatoid arthritis; ultrasound
01 Pubblicazione su rivista::01a Articolo in rivista
The role of musculoskeletal ultrasound in predicting the response to JAK inhibitors. results from a monocentric cohort / Ceccarelli, Fulvia; Spinelli, Francesca Romana; Garufi, Cristina; Mancuso, Silvia; Alessandri, Cristiano; Di Franco, Manuela; Orefice, Valeria; Pacucci, Viviana Antonella; Pirone, Carmelo; Priori, Roberta; Riccieri, Valeria; Sili Scavalli, Antonio; Scrivo, Rossana; Truglia, Simona; Conti, Fabrizio. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 1593-098X. - 40:5(2022), pp. 921-927. [10.55563/clinexprheumatol/totvyv]
File allegati a questo prodotto
File Dimensione Formato  
Ceccarelli_Role_2022.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 623.4 kB
Formato Adobe PDF
623.4 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1706308
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact